Stock

Akebia Therapeutics, Inc. AKBA

$1.22-0.82%

All stocks Create account to unlock

Overview

AKBA market data

Price History

AKBA price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for AKBA. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

4 captured

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target · Jul 1, 2026, 11:55 AM

Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study After Planned Interim Analysis Based On Recommendation From Independent Data Monitoring Committee, Trial Steering Committee · Jun 30, 2026, 12:15 PM

8-K filing — Akebia Therapeutics, Inc. (AKBA) · Jun 30, 2026, 12:05 PM

Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight · Jun 23, 2026, 5:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock